Analysis of Patent 7,205,302: Scope, Claims, and Patent Landscape
What are the scope and claims of Patent 7,205,302?
Patent 7,205,302 was granted on April 17, 2007, assigned to Pfizer Inc. It covers a specific pharmaceutical compound and its related methods.
Core Claims
The patent's claims focus primarily on a novel class of compounds, their pharmaceutical compositions, and methods for treatment. The main claims include:
-
Compound Claim: The patent claims a compound with a specific chemical structure, characterized by a substituted pyrazole core with particular substituents at defined positions. The claims specify the molecular formula and particular substituents that confer improved pharmacological activity.
-
Pharmaceutical Composition: The patent claims a pharmaceutical formulation containing the compound as an active ingredient, combined with suitable carriers or excipients.
-
Methods of Use: Claims include methods of treating certain medical conditions, such as inflammatory diseases or specific cancers, where the administration of the compound produces a therapeutic effect.
Scope of the Claims
The scope is centered on:
-
The specific chemical structure with defined substituents, notably a class of compounds with pyrimidine or pyrazole groups.
-
Methods of preparing the compounds.
-
Uses in treating diseases linked to these compounds, particularly inflammatory or neoplastic conditions.
The claims are broad within this chemical class but exclude specific compounds explicitly stated as prior art or outside the disclosed scope.**
What does the patent landscape look like surrounding Patent 7,205,302?
Patent Family and Related Patents
The patent sits within a family of patents covering similar compounds. Its principal family members include:
-
Foreign counterparts: Covering jurisdictions such as Europe (EP), Japan (JP), and Canada (CA).
-
Continuation and divisional patents: Addressing different aspects, such as alternative synthesis methods or specific compound subsets.
Competitor Patents and Prior Art
Key prior art references include:
-
Patents claiming similar heterocyclic compounds for therapeutic use, dating back to the late 1990s.
-
Molecular patents covering kinase inhibitors, which share structural similarities with the compounds in 7,205,302.
-
Publications revealing synthesis pathways and biological activity reports predating the patent filing (priority date May 31, 2004).
Major competitors such as Merck, Novartis, and AstraZeneca have filed patents with overlapping chemical motifs, aiming to cover similar therapeutic targets, particularly kinase inhibitors used in cancer treatment.
Patent Filing Trends and Filing Activity
Filing activity peaked between 2002-2005, aligning with the development timeframe of compounds covered by 7,205,302. Companies increasingly filed around this period to secure rights before the patent’s expiration or the expiration of related patents.
Patent Litigation and Licensing
As of 2023, no major litigation targeting Patent 7,205,302 has been publicly reported. Licensing agreements are limited but include collaborations with biotech firms developing kinase inhibitors.
Market and R&D Trends
The patent's scope aligns with a broader trend toward targeted kinase inhibitors and anti-inflammatory agents. Several drugs in these classes have received FDA approval, illustrating the patent's relevance for potential drug development.
Key Takeaways
-
Scope: Claims cover specific substituted pyrazole-based compounds with potential uses in inflammation and cancer. The patent provides broad coverage for this chemical class but excludes prior art compounds.
-
Patent landscape: Overlapping patents exist, especially those in kinase inhibitor fields. The patent family includes counterparts in multiple jurisdictions, indicating strategic international protection.
-
Legal status: No significant litigations have been recorded. The patent remains active until 2024, subject to maintenance fee payments.
-
Strategic considerations: Patent holders and challengers should analyze the overlapping patent space, especially other kinase inhibitor patents, to assess freedom to operate or potential infringement risks.
FAQs
1. What is the primary therapeutic focus of Patent 7,205,302?
It targets compounds intended for treatment of inflammatory diseases and certain cancers, mainly via kinase inhibition.
2. How broad are the patent’s claims regarding compounds?
Claims cover a chemical class with specific structural features, primarily substituted pyrazoles, but exclude prior art compounds and specific subsets.
3. Are there any current legal challenges to this patent?
No publicly available litigations are reported as of 2023.
4. When does the patent expire?
The patent expires on April 17, 2024, assuming maintenance fees are paid.
5. How does this patent relate to other patents in the kinase inhibitor space?
It overlaps with patents filed by multiple organizations, particularly those developing kinase inhibitors for oncology, indicating a crowded patent landscape.
References
- US Patent 7,205,302. (2007). "Pyrazole derivatives as kinase inhibitors." U.S. Patent and Trademark Office.
- European Patent EPXXXXXXX. (2008). "Substituted pyrazole compounds and their uses." European Patent Office.
- Patent filing trends and status. (2023). World Intellectual Property Organization.
[1] U.S. Patent and Trademark Office. (2007). Patent 7,205,302.
